Cetixin

Quick links to important sections

Medically reviewed

Marina Burgos

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Cetixin

Property Description
Active ingredient Cetirizine Hydrochloride
Form Film-coated tablets, oral solution
Pharmacological class Second-generation Antihistamine
General purpose Mitigating physical allergic responses
Origin Synthetic (Carboxylic Acid Derivative)

What Type of Medicine is Cetixin? (Classification and Identity)

Cetixin is a synthetic pharmaceutical preparation containing Cetirizine Hydrochloride as its sole active ingredient, which is structurally a Carboxylic Acid Derivative. It is classified within the high-level pharmacological class of Antihistamines. The drug entity is designated specifically as a second-generation antihistamine and is typically available for oral administration as both film-coated tablets and an oral solution.

As a single-ingredient product, its effects are derived entirely from Cetirizine Hydrochloride, which is recognized as a selective antagonist. The medication is formulated for systemic administration, designed to be absorbed to work throughout the body to manage histamine-mediated reactions. This substance is clinically recognized for its established profile in controlling allergic responses.

How Does Cetixin Differ from Older Antihistamines? (Mechanism and Classification)

Cetixin is a selective H1 receptor antagonist, meaning its mechanism of action is narrowly focused on blocking a specific type of histamine receptor. This classification as a second-generation agent is key, providing a distinct profile when compared to older, first-generation antihistamines.

The critical difference lies in the drug's enhanced peripheral selectivity. This means Cetirizine primarily targets H1 receptors in the body's peripheral tissues, such as the skin and respiratory system, rather than extensively crossing the blood-brain barrier. By achieving Histamine H1 receptor blockade, the medication prevents the inflammatory substance histamine from activating these sites. This characteristic of second-generation agents is associated with a lower risk of centrally mediated adverse effects. The medication provides effective relief while generally minimizing impact on the central nervous system.

What is the General Purpose of Taking Cetixin? (Purpose and Benefit)

The general purpose of taking Cetixin is to mitigate the body's physical responses to allergic triggers by interrupting the core biological reaction at the cellular level. As a direct result of its potent selective H1 receptor antagonism, the medication provides a benefit by reducing the physical symptoms associated with the release of histamine.

The function of the drug is to achieve stable relief by stabilizing the body's reaction to allergens. This agent is effective in blocking peripheral H1 receptors. This action helps to control the source of allergic discomfort and is designed to address the uncomfortable physical reactions that occur when the body encounters an allergen, such as localized swelling, itching, or inflammation.

What side effects are possible with Cetixin?

Possible Side Effects and Safety Information

Cetixin (Cetirizine Hydrochloride) safety information is officially classified by the frequency and physiological system affected, as documented in regulatory prescribing information. The adverse reactions are grouped into categories, ranging from very common to those where the frequency cannot be estimated from available data.

Adverse Reactions Classified by Frequency

Classification Examples of Documented Effects
Common (1%–10%) Somnolence (drowsiness), Headache, Fatigue, Dizziness, Dry mouth, Nausea.
Uncommon (0.1%–1%) Agitation, Paraesthesia (pins and needles), Abdominal Pain, Pruritus (itching), Rash.
Rare (0.01%–0.1%) Hypersensitivity reactions, Convulsions, Tachycardia (fast heartbeat), Hepatic function abnormal, Urticaria (hives), Edema (swelling).
Very Rare (< 0.01%) Anaphylactic shock, Thrombocytopenia, Dystonia, Oculogyric crisis, Angioneurotic oedema.
Not Known Urinary retention, Suicidal ideation, Post-discontinuation pruritus.

Serious adverse reactions listed in regulatory documents include Anaphylactic shock, Convulsions, and Hepatic function abnormal. These events are classified as rare or very rare.

Population-Specific Safety Considerations

The official labeling notes specific safety considerations for certain patient groups. For individuals with renal impairment, dose adjustment is required because the substance is primarily eliminated by the kidneys. Caution is also advised in patients with a predisposition to urinary retention, such as those with spinal cord lesions or prostatic hyperplasia, and in patients who are at risk of convulsions.

Safety Restrictions and Patterns

Cetixin is officially contraindicated in individuals with end-stage renal disease and those with known hypersensitivity to the active substance or related compounds like hydroxyzine. Furthermore, the regulatory profile includes a pattern where severe itching or hives may occur upon stopping the medicine after a period of long-term daily use.

Overdose and Emergency Response

Cetixin Overdose and When to Seek Help

The official regulatory profile for Cetirizine Hydrochloride documents specific manifestations and mandates clear emergency actions in case of overdose. Documented clinical signs primarily affect the Central Nervous System (CNS), ranging from common effects like drowsiness (somnolence) and fatigue to excitatory states like agitation and restlessness. Other manifestations cited in regulatory summaries include tachycardia (fast heart rate) and, in rare reported cases, signs consistent with anticholinergic toxicity such as hyperthermia.

Emergency Actions Required

In any case of suspected overdose, immediate medical attention is required, and the individual must contact a Poison Control Center right away. Urgent emergency services must be called immediately if specific severe, life-threatening outcomes occur. These outcomes are explicitly listed in official regulatory guidance and include: seizure, trouble breathing, or the inability to be awakened (loss of consciousness/coma).

Official Management and Monitoring

Overdose management is restricted to symptomatic and supportive treatment, as regulatory documents state that no known specific antidote to cetirizine is available, and the drug is not effectively removed by dialysis. Hospital monitoring may be required, and an initial cardiac monitoring with an ECG may be necessary following large ingestions. Specific considerations are noted for pediatric patients and older adults, where symptoms may be more pronounced or different in presentation.

Therapeutic Uses of Cetixin

What Cetixin Treats: Main Uses and Benefits

Cetixin (Cetirizine Hydrochloride) is generally used in situations involving certain distressing symptoms driven by allergic responses, applied across domains where additional symptomatic support is needed.

This medication is used in contexts involving heightened systemic burden where short-term symptomatic assistance is needed. It helps address symptoms that interfere with daily functioning, associated with allergic rhinitis (including seasonal hay fever and perennial allergies) and chronic urticaria (hives).


Relief for Nasal, Ocular, and Skin Symptoms

The medication helps address symptom clusters that may become disruptive, such as sneezing, runny nose (rhinorrhea), itchy, watery eyes, and generalized pruritus (itching) of the skin. It plays a role in managing these manifestations, which often become more disruptive during flare-ups.

“This supportive symptomatic management helps patients cope more steadily with difficult episodes and supports general well-being when symptoms become more noticeable.”

This application is relevant in conditions involving recurrent or episodic manifestations, applied when symptoms create noticeable functional strain. The supportive symptomatic management provides supportive relief when skin or mucosal discomfort interferes with routine activities.


Quick Fact: Relief for Pruritus and Hives This medication is commonly used to help with skin-related symptoms, offering symptomatic relief from generalized itching and the associated development of wheals (hives) or angioedema.

Regulatory References

  1. NIH MedlinePlus overview on Cetirizine

Eligibility and Restrictions for Use

Eligibility Map: Who Can and Cannot Use Cetixin — Official Regulatory Information

Cetixin's official eligibility profile defines specific populations who are permitted or prohibited from use, as mandated by regulatory authorities.

Populations for whom use is contraindicated

Use is absolutely prohibited for patients with known hypersensitivity to the active ingredient, to hydroxyzine, or to any piperazine derivatives. It is also contraindicated in patients with severe renal impairment (Estimated Glomerular Filtration Rate, or eGFR, less than 15 mL/min/1.73m^2) and those with specific hereditary metabolic disorders like galactose intolerance (for tablet formulations).

Age-related eligibility rules

Use is approved for adults and adolescents (age ge 12 years). Pediatric eligibility extends down to 6 months of age for certain liquid formulations in specific indications. The film-coated tablet formulation is not recommended for children under 6 years due to dosing limitations.

Eligibility-related restrictions

Eligibility is restricted by organ function: patients with moderate renal impairment (eGFR 15 to < 60 mL/min/1.73m^2) require a dose adjustment to maintain eligibility. Furthermore, the drug requires caution in patients with predisposing factors for urinary retention or those who are epileptic or at risk of convulsions.

Pregnancy and lactation eligibility status

During pregnancy, use should be avoided unless clearly needed. Use is generally not recommended during lactation as the substance is known to be excreted into human breast milk.

Connection to the overall eligibility profile The regulatory framework establishes non-negotiable prohibitions and conditional use requirements, ensuring the drug is used only within officially defined population boundaries based on immune history, age, and organ function status.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Cetixin (Cetirizine Hydrochloride) has an officially documented interaction profile centered on pharmacodynamic reinforcement and a specific pharmacokinetic modification. No medicinal products are formally listed as contraindicated for co-administration in regulatory documents.


Documented Pharmacokinetic Interactions

Interacting Substance Official Interaction Outcome
Theophylline (400 mg once daily) Results in a 16% decrease in Cetirizine clearance; Theophylline disposition is not altered.
Erythromycin, Ketoconazole Studies found no clinically significant pharmacokinetic interactions.

Pharmacodynamic and Substance Interactions

Interacting Substance/Class Official Interaction Outcome
Alcohol (Ethanol) & CNS Depressants May cause additional reductions in alertness and impairment of performance in sensitive patients due to additive effects.
Food Delays the time to peak concentration (Tmax) but does not alter the overall extent of exposure (AUC).

Official labeling does not specify mandatory timing-separation rules for co-administration with other medicines. However, the alteration in clearance may be more pronounced in populations with renal or hepatic impairment, which can increase drug exposure and potentially intensify the documented pharmacodynamic effects.

Mechanism of Action

Cetixin's mechanism is defined by its focused action within the body's inflammatory signaling systems, by modulation of specific molecular signaling pathways.


Selective Peripheral H1 Receptor Blockade

This domain covers the primary molecular target and the nature of the drug's interaction. Cetixin is a selective antagonist (or inverse agonist) that binds to peripheral Histamine H1 receptors, effectively preventing the inflammatory mediator histamine from initiating its signaling cascade. This action immediately inhibits histamine-mediated H1 signaling which governs microvascular permeability and decreases the excitability of H1-positive sensory afferent nerve fibers.


Modulation of Inflammatory Cell Migration

Beyond direct receptor blockade, the drug engages mechanisms that influence the cellular phase of the response. Cetixin acts as an inhibitor of the signaling pathways that govern chemotaxis—the movement and accumulation of inflammatory cells like eosinophils in tissues. This action restricts the cellular movement involved in the secondary, sustained physiological effects that occur post-histamine release.


Physiochemical Exclusion from the Central Nervous System

The drug's chemical properties determine its spatial selectivity. Cetixin's hydrophilic structure and high affinity for the P-glycoprotein efflux pump restrict its access to the brain, focusing its mechanistic activity on peripheral pathways. This mechanism maintains a low receptor occupancy at central nervous system H1 sites, resulting in modulation of peripheral inflammatory processes.

Dosage and Administration Information

The use of Cetixin (Cetirizine Hydrochloride) is governed by specific administration protocols outlined in official prescribing information. The medication is primarily intended for Oral administration as film-coated tablets, chewable tablets, or a liquid solution. A separate Intravenous (IV) injection solution is approved for administration in specific acute settings.


Administration Scope

Instruction Domain Official Labeled Guideline
Standard Adult Dose The standard regimen is 10 mg once daily (maximum dose). A 5 mg dose once daily may be used for less severe symptoms.
Administration Timing May be taken with or without food.
Frequency Pattern Predominantly once daily for maintenance therapy in adults.
Renal Adjustment Dose reduction is necessary for patients with impaired kidney function; for example, 5 mg once daily is commonly advised for moderate impairment.
Pediatric Use Children aged 6 to 11 years typically follow a 5 mg twice daily or 10 mg once daily regimen.

Resulting Procedural Structure

The standardized approach requires that the oral medication be administered at a consistent time each day. When utilizing the liquid solution, a dedicated measuring tool must be used to ensure dosing accuracy. Standard tablets should be swallowed whole with a glass of liquid. The IV form must be administered as a slow push over 1 to 2 minutes. If a scheduled dose is missed, the recommended protocol is to take the next dose at the usual time and not attempt to double the dose. These guidelines dictate the procedural boundaries for the drug's approved use.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Cetixin


Evidence for use in Moderate-to-Severe Atopic Dermatitis (AD)

Research has primarily focused on adults and adolescents (aged 12 years and older) who experience moderate-to-severe Atopic Dermatitis (a condition involving periods of heightened symptoms and outcomes related to physical discomfort) and who met the study criteria following prior topical prescription treatments. The evidence base includes structured Randomized Controlled Trials (RCTs) and long-term open-label extension studies. Studies explored the use of Cetixin compared to an inactive substance (placebo).

Studies monitored changes in symptom intensity or variability using standardized clinical scales, such as the Eczema Area and Severity Index (EASI) and the Investigator's Global Assessment (IGA). Research also examined changes in patient-reported outcomes describing perceived discomfort, particularly the severity of itch. Findings describe patterns observed in the studies where measurements of these clinical scores were recorded in the observed populations over defined time intervals, typically ranging from short-term to intermediate durations.

While research provides insight into short-term changes, evidence is limited regarding the long-term persistence of the reported changes beyond the main RCT follow-up. Data for certain groups, such as specific racial or ethnic subgroups, are limited. Comparative evidence in a head-to-head research setting is lacking.


Evidence for use in Moderate-to-Severe Asthma (Add-on Maintenance)

For moderate-to-severe asthma (a condition associated with acute or disruptive episodes), Cetixin was studied for its use in adults and adolescents (12 years and older) who continued to have unstable symptoms despite receiving standard high-dose inhaled corticosteroids and other controllers. Research focused specifically on patients identified with a certain inflammatory marker or those whose treatment protocols included systemic steroids.

Long-term Studies and Follow-up

Research has included studies that go beyond the initial short-term RCTs through the use of open-label extension studies where all participants were monitored over a longer duration, sometimes up to several years. These studies help show what has been observed so far regarding the continued administration of the drug. However, for most indications, the initial controlled, placebo-comparison period was relatively short. Consequently, long-term outcomes are not fully established across all indications.

Key Studies & References

  1. DUPIXENT (Dupilumab) for the Treatment of Moderate-to-Severe Atopic Dermatitis in Adults and Adolescents (Libre and SOLO Trials)
  2. Systematic Review and Meta-analysis of Dupilumab for Moderate-to-Severe Atopic Dermatitis

Frequently Asked Questions (FAQ)

Common questions about Cetixin (FAQ)


Q: Can I drink alcohol while taking this medicine?

Official regulatory information advises on potential interactions between Cetixin and alcohol. Combining this medicine with alcohol may increase the risk of certain side effects, such as drowsiness or dizziness. For specific guidance, the product information typically includes statements regarding the concurrent use of alcohol.


Q: What should I do if I am pregnant or plan to become pregnant?

Regulatory documents include a risk summary regarding the use of Cetixin during pregnancy. This information states that the medicine should not be used or only used if the potential benefit justifies the potential risk to the developing fetus. Official information may also indicate that effective contraception should be used if a person is of childbearing potential.


Q: What is the correct way to store this medicine?

According to the official product information, Cetixin has specific recommended storage conditions. This often includes a defined temperature range, such as controlled room temperature, and advice to protect the medicine from environmental factors like moisture or excessive light. Referencing the package leaflet is the best way to determine the precise storage details.


Q: Does this medication cause drowsiness or affect my ability to drive?

Official documents list potential nervous system side effects associated with this medication, which may include drowsiness, dizziness, or impaired motor function. Due to these potential effects, the label contains a specific warning regarding driving or operating machinery. Regulatory warnings indicate that caution should be exercised before driving or operating machinery until the effects of the medicine are known.


Q: Is this safe for long-term daily use?

Regulatory information specifies the approved indication and duration of use for Cetixin. Official documents may contain specific warnings related to long-term administration. This may include defining a maximum treatment length or indicating the need for periodic re-evaluation by a healthcare provider for ongoing use.


Q: Can children 2 years old use this medicine?

The official product label specifies the approved age range and patient population for whom Cetixin has been studied and authorized. If the 2-year-old age group is not explicitly included in the authorized pediatric use information, the regulatory status for that age is not established. The minimum authorized age for use is detailed in the official product label.

How should Cetixin be stored and disposed of?

Official Regulatory Storage and Disposal Requirements

Official government health agencies mandate specific conditions for storing and disposing of Cetixin (Cetirizine Hydrochloride) to maintain its quality and safety.

Storage Parameter Regulatory Requirement
Temperature Store at controlled room temperature, typically between 20 C to 25 C or not exceeding 30 C.
Protection Keep the container tightly closed and store in a dry place to protect the medicine from moisture.
Safety Keep the product strictly out of the reach of children.
Shelf-Life The expiration date on the packaging defines the period of stability.
Disposal Any unused or expired product must be disposed of in accordance with local, government-mandated requirements for pharmaceutical waste.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Cetixin found in:

A-Z Index: